Chakma Justin, Chief Business Officer of ARS Pharmaceuticals ($SPRY), sold shares on the open market twice in the last year, totaling $1.5 million. His most recent sale occurred on November 12, 2025. These sales rank 4,092nd among 11,678 insiders in our database, where the average is $8.6 million across about 6.4 transactions per insider. Chakma Justin made no open market purchases during this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan. 2, 2026 | ARS Pharmaceuticals, Inc. | $SPRY | Chakma Justin | Chief Business Officer | A | Stock option (right to buy) | 240000 | $0.00 | 240,000.0000 | 98,807,600 | 9999.99% | 0.24% |
| Nov. 12, 2025 | ARS Pharmaceuticals, Inc. | $SPRY | Chakma Justin | Chief Business Officer | M | Common Stock | 30000 | $0.84 | 166,380.0000 | 98,807,600 | 22.00% | 0.03% |
| Nov. 12, 2025 | ARS Pharmaceuticals, Inc. | $SPRY | Chakma Justin | Chief Business Officer | M | Stock Option (Right to Buy) | 30000 | $0.00 | 89,047.0000 | 98,807,600 | 25.20% | 0.03% |
| Nov. 12, 2025 | ARS Pharmaceuticals, Inc. | $SPRY | Chakma Justin | Chief Business Officer | S | Common Stock | 136380 | $8.86 | 0.0000 | 98,807,600 | 100.00% | 0.14% |
| Nov. 12, 2025 | ARS Pharmaceuticals, Inc. | $SPRY | Chakma Justin | Chief Business Officer | S | Common Stock | 30000 | $8.91 | 136,380.0000 | 98,807,600 | 18.03% | 0.03% |
| Jan. 2, 2025 | ARS Pharmaceuticals, Inc. | $SPRY | Chakma Justin | Chief Business Officer | A | Stock option (right to buy) | 274100 | $0.00 | 274,100.0000 | 102,390,828 | 9999.99% | 0.27% |
| Dec. 13, 2024 | ARS Pharmaceuticals, Inc. | $SPRY | Chakma Justin | Chief Business Officer | M | Stock Option (Right to Buy) | 27272 | $0.00 | 55,461.0000 | 97,032,331 | 32.96% | 0.03% |
| Dec. 12, 2024 | ARS Pharmaceuticals, Inc. | $SPRY | Chakma Justin | Chief Business Officer | M | Stock Option (Right to Buy) | 117333 | $0.00 | 119,047.0000 | 97,032,331 | 49.64% | 0.12% |
| Dec. 13, 2024 | ARS Pharmaceuticals, Inc. | $SPRY | Chakma Justin | Chief Business Officer | S | Common Stock | 27272 | $12.06 | 136,380.0000 | 97,032,331 | 16.66% | 0.03% |
| Dec. 13, 2024 | ARS Pharmaceuticals, Inc. | $SPRY | Chakma Justin | Chief Business Officer | M | Common Stock | 27272 | $1.44 | 163,652.0000 | 97,032,331 | 20.00% | 0.03% |
| Dec. 12, 2024 | ARS Pharmaceuticals, Inc. | $SPRY | Chakma Justin | Chief Business Officer | S | Common Stock | 117333 | $12.27 | 136,380.0000 | 97,032,331 | 46.25% | 0.12% |
| Dec. 12, 2024 | ARS Pharmaceuticals, Inc. | $SPRY | Chakma Justin | Chief Business Officer | M | Common Stock | 117333 | $0.84 | 253,713.0000 | 97,032,331 | 86.03% | 0.12% |
| Dec. 10, 2024 | ARS Pharmaceuticals, Inc. | $SPRY | Chakma Justin | Chief Business Officer | M | Stock Option (Right to Buy) | 50000 | $0.00 | 0.0000 | 97,032,331 | 100.00% | 0.05% |
| Dec. 10, 2024 | ARS Pharmaceuticals, Inc. | $SPRY | Chakma Justin | Chief Business Officer | S | Common Stock | 50000 | $13.15 | 136,380.0000 | 97,032,331 | 26.83% | 0.05% |
| Dec. 10, 2024 | ARS Pharmaceuticals, Inc. | $SPRY | Chakma Justin | Chief Business Officer | M | Common Stock | 50000 | $0.84 | 186,380.0000 | 97,032,331 | 36.66% | 0.05% |
| Dec. 6, 2024 | ARS Pharmaceuticals, Inc. | $SPRY | Chakma Justin | Chief Business Officer | S | Common Stock | 50000 | $14.23 | 136,380.0000 | 97,032,331 | 26.83% | 0.05% |
| Dec. 4, 2024 | ARS Pharmaceuticals, Inc. | $SPRY | Chakma Justin | Chief Business Officer | M | Stock Option (Right to Buy) | 45000 | $0.00 | 149,640.0000 | 97,032,331 | 23.12% | 0.05% |
| Dec. 5, 2024 | ARS Pharmaceuticals, Inc. | $SPRY | Chakma Justin | Chief Business Officer | M | Stock Option (Right to Buy) | 49640 | $0.00 | 100,000.0000 | 97,032,331 | 33.17% | 0.05% |
| Dec. 6, 2024 | ARS Pharmaceuticals, Inc. | $SPRY | Chakma Justin | Chief Business Officer | M | Stock Option (Right to Buy) | 50000 | $0.00 | 50,000.0000 | 97,032,331 | 50.00% | 0.05% |
| Dec. 5, 2024 | ARS Pharmaceuticals, Inc. | $SPRY | Chakma Justin | Chief Business Officer | M | Common Stock | 49640 | $0.84 | 186,020.0000 | 97,032,331 | 36.40% | 0.05% |
| Dec. 5, 2024 | ARS Pharmaceuticals, Inc. | $SPRY | Chakma Justin | Chief Business Officer | S | Common Stock | 49640 | $14.13 | 136,380.0000 | 97,032,331 | 26.69% | 0.05% |
| Dec. 6, 2024 | ARS Pharmaceuticals, Inc. | $SPRY | Chakma Justin | Chief Business Officer | M | Common Stock | 50000 | $0.84 | 186,380.0000 | 97,032,331 | 36.66% | 0.05% |
| Dec. 4, 2024 | ARS Pharmaceuticals, Inc. | $SPRY | Chakma Justin | Chief Business Officer | M | Common Stock | 45000 | $0.84 | 181,380.0000 | 97,032,331 | 33.00% | 0.05% |
| Dec. 4, 2024 | ARS Pharmaceuticals, Inc. | $SPRY | Chakma Justin | Chief Business Officer | S | Common Stock | 45000 | $13.95 | 136,380.0000 | 97,032,331 | 24.81% | 0.05% |
| Dec. 2, 2024 | ARS Pharmaceuticals, Inc. | $SPRY | Chakma Justin | Chief Business Officer | M | Stock Option (Right to Buy) | 45000 | $0.00 | 3,260.0000 | 97,032,331 | 93.24% | 0.05% |
| Dec. 3, 2024 | ARS Pharmaceuticals, Inc. | $SPRY | Chakma Justin | Chief Business Officer | M | Stock Option (Right to Buy) | 3260 | $0.00 | 0.0000 | 97,032,331 | 100.00% | 0.00% |
| Dec. 3, 2024 | ARS Pharmaceuticals, Inc. | $SPRY | Chakma Justin | Chief Business Officer | M | Stock Option (Right to Buy) | 41740 | $0.00 | 194,640.0000 | 97,032,331 | 17.66% | 0.04% |
| Dec. 3, 2024 | ARS Pharmaceuticals, Inc. | $SPRY | Chakma Justin | Chief Business Officer | M | Common Stock | 3260 | $0.84 | 139,640.0000 | 97,032,331 | 2.39% | 0.00% |
| Dec. 2, 2024 | ARS Pharmaceuticals, Inc. | $SPRY | Chakma Justin | Chief Business Officer | S | Common Stock | 45000 | $13.67 | 136,380.0000 | 97,032,331 | 24.81% | 0.05% |
| Dec. 2, 2024 | ARS Pharmaceuticals, Inc. | $SPRY | Chakma Justin | Chief Business Officer | M | Common Stock | 45000 | $0.84 | 181,380.0000 | 97,032,331 | 33.00% | 0.05% |
| Dec. 3, 2024 | ARS Pharmaceuticals, Inc. | $SPRY | Chakma Justin | Chief Business Officer | M | Common Stock | 41740 | $0.84 | 181,380.0000 | 97,032,331 | 29.89% | 0.04% |
| Dec. 3, 2024 | ARS Pharmaceuticals, Inc. | $SPRY | Chakma Justin | Chief Business Officer | S | Common Stock | 45000 | $13.19 | 136,380.0000 | 97,032,331 | 24.81% | 0.05% |
| Nov. 25, 2024 | ARS Pharmaceuticals, Inc. | $SPRY | Chakma Justin | Chief Business Officer | S | Common Stock | 32814 | $14.00 | 203,566.0000 | 97,032,331 | 13.88% | 0.03% |
| Nov. 26, 2024 | ARS Pharmaceuticals, Inc. | $SPRY | Chakma Justin | Chief Business Officer | S | Common Stock | 42186 | $14.05 | 161,380.0000 | 97,032,331 | 20.72% | 0.04% |
| Nov. 27, 2024 | ARS Pharmaceuticals, Inc. | $SPRY | Chakma Justin | Chief Business Officer | S | Common Stock | 25000 | $14.39 | 136,380.0000 | 97,032,331 | 15.49% | 0.03% |
| Jan. 2, 2024 | ARS Pharmaceuticals, Inc. | $SPRY | Chakma Justin | Chief Business Officer | A | Stock option (right to buy) | 350000 | $0.00 | 350,000.0000 | 95,215,322 | 9999.99% | 0.37% |
| Jan. 3, 2023 | ARS Pharmaceuticals, Inc. | $SPRY | Chakma Justin | Chief Business Officer | A | Stock option (right to buy) | 165000 | $0.00 | 165,000.0000 | 0 | 9999.99% | 0.00% |